

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Jean-Luc IMLER et al.

Application No.: 09/218,143

Filed: December 22, 1998

For: DEFECTIVE ADENOVIRUSES AND
CORRESPONDING
COMPLEMENTATION LINES



) Group Art Unit: 1632

) Examiner: S. Priebe

)

)

)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below, were submitted or referenced in parent Application Serial No. 08/379,452. Thus, these documents are not enclosed herewith.

FOREIGN PATENTS

1. International Publication No. WO 94/28152, published December 8, 1994.
2. International Publication No. WO 93/06223, published April 1, 1993.

OTHER DOCUMENTS

3. V. Krougliak et al., *Human Gene Therapy*, 6:1575-1586 (1995).
4. P. Yeh et al., *Journal of Virology*, 70(1):559-565 (1996).
5. Q. Wang et al., *Gene Therapy*, 2:775-783 (1995).

6. F. Fallaux et al., *Human Gene Therapy*, 9:1909-1917 (1998).
7. F. Fallaux et al., *Human Gene Therapy*, 7:215-222 (1996).
8. A. Senear et al., *Molecular and Cellular Biology*, 6(4):1253-1260 (1986).
9. R. Bernards et al., *Virology*, 120:422-432 (1982).
10. B. Roberts et al., *Journal of Virology*, 56(2):404-413 (1985).
11. R.T.M.J. Vaessen et al., *The EMBO Journal*, 5(2):335-341.
12. N. Louis et al., *Virology*, 233:423-429 (1997).
13. J. Chroboczek et al., *Virology*, 186:280-285 (1992).
14. K.L. Berkner, *Current Topics in Microbiology and Immunology*, 158:39-66 (1992).
15. M. Grable et al., *Journal of Virology*, 64(5):2047-2056.
16. D. Armentano et al., *Human Gene Therapy*, 6:1343-1353 (1995).
17. D. Klessig et al., *Molecular and Cellular Biology*, 4(7):1354-1362 (1984).
18. J. Engelhardt et al., *Proc. Natl. Acad. Sci.*, 91:6196-6200 (1994).
19. G.P. Gao et al., *Journal of Virology*, 70(12):8934-8943 (1996).
20. A. Mastrangeli et al., *The Journal of Clinical Investigation, Inc.*, 91:225-234 (1993).
21. M. Rosenfeld et al., *Science*, 252:431-434 (1991).
22. V. Randrianarison-Jewtoukoff et al., *Biologicals*, 23:145-157 (1995).
23. B.C. Trapnell et al., *Current Opinion in Biotechnology*, 5:617-625 (1994).
24. M. Lusky et al., *Journal of Virology*, 72(3):2022-2032 (1998).


25. Q. Wang et al., *Gene Therapy*, 4:393-400 (1997).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the above-cited documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialled copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Susan M. Dadio
Registration No. 40,373

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: September 9, 1999

RECEIVED

SEP 2 / 1999

TECH CENTER 1600/2900 Patent
Attorney's Docket No. 029395-005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Jean-Luc IMLER et al.

Application No.: 09/218,143

Filed: December 22, 1998

For: DEFECTIVE ADENOVIRUSES AND
CORRESPONDING
COMPLEMENTATION LINES



Group Art Unit: 1632

Examiner: S. Priebe

RECEIVED

SEP 10 1999

TECH CENTER 1600/2900

RECEIVED

SEP 2 / 1999

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the
above-identified patent application.

- ☒ [X] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$240.00 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e), a petition requesting consideration of the
information disclosure statement, and the petition fee of \$130.00 as set forth in 37
C.F.R. § 1.17(i) are also enclosed.
- ☐ [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$_____ is enclosed for the fee due.

Information Disclosure Statement Transmittal Letter

Application No. 09/218,143


Attorney's Docket No. 029395-005

Page 2

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in triplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Susan M. Dadio
Registration No. 40,373

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: September 9, 1999